Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last SFr.0.48 CHF
Change Today 0.00 / 0.00%
Volume 913.0K
CYTN On Other Exchanges
As of 11:43 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

cytos biotechnology ag-reg (CYTN) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/6/15 - SFr.2.60
52 Week Low
10/7/14 - SFr.0.15
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

cytos biotechnology ag-reg (CYTN) Related Businessweek News

No Related Businessweek News Found

cytos biotechnology ag-reg (CYTN) Details

Cytos Biotechnology AG focuses on the development and commercialization of biopharmaceutical products for use in the treatment and prevention of chronic diseases. The company has collaborative research, option, and license agreement with Novartis for the development of CAD106, an active immunotherapy for the treatment of patients with Alzheimer’s disease; license agreement with Pfizer Inc. for developing an anti-IgE vaccine; and collaborative research, development, and commercialization agreement with Singapore’s Agency for Science, Technology and Research. Cytos Biotechnology AG is based in Schlieren, Switzerland.

3.5 Employees
Last Reported Date: 07/23/15

cytos biotechnology ag-reg (CYTN) Top Compensated Officers

Chairman, Chief Executive Officer, Member of ...
Total Annual Compensation: SFr.546.0K
Compensation as of Fiscal Year 2014.

cytos biotechnology ag-reg (CYTN) Key Developments

Cytos Biotechnology Ltd Exclusively Licenses VLP Platform for the Treatment of Cancer to Checkmate Pharmaceuticals LLC

Cytos Biotechnology Ltd. announced that it executed an exclusive license agreement in the field of oncology granting Checkmate Pharmaceuticals LLC, Cambridge, MA, USA exclusive access to Cytos' clinically validated product candidate CYT003 as well as its VLP platform and to technology related to oligonucleotide synthesis. Cytos may receive up to USD 90 million in development milestones and may receive up to double-digit royalties on net sales from successfully developed products.

Cytos Biotechnology Ltd Reports Earnings Results for the First Half Year Ended June 30, 2015

Cytos Biotechnology Ltd. reported earnings results for the first half year ended June 30, 2015. For the first half year, the company reported revenue of CHF 4.5 million against CHF 0.5 million a year ago. Operating income was CHF 2.2 million against operating loss of HF 16.0 million a year ago. Net income was CHF 7.8 million against net loss of CHF 23.4 million a year ago. This significant decrease is mostly based on one-time effects related to the elimination of debt as described above, as well as the revenue from the amendment of the collaboration and license agreement for CAD 106 by Novartis.

Cytos Biotechnology AG, Annual General Meeting, Jun 29, 2015

Cytos Biotechnology AG, Annual General Meeting, Jun 29, 2015., at 11:00 Central European Standard Time. Location: Schlieren.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CYTN:SW SFr.0.48 CHF 0.00

CYTN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CYTN.
View Industry Companies

Industry Analysis


Industry Average

Valuation CYTN Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CYTOS BIOTECHNOLOGY AG-REG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at